FiercePharma News http://www.fiercepharma.com/news/feed/frontpage en Valeant, Actavis on verge of FDA nods in IBS for Xifaxan, eluxadoline http://www.fiercepharma.com/story/valeant-actavis-verge-fda-nods-ibs-xifaxan-eluxadoline/2015-05-26?utm_medium=rss&utm_source=rss&utm_campaign=rss <p>Get ready for a showdown in the irritable bowel syndrome market.</p> Actavis Regulatory Valeant Pharmaceuticals Tue, 26 May 2015 14:57:22 +0000 Tracy Staton 303936 at http://www.fiercepharma.com GSK, Pfizer among Big Pharmas bailing on Chinese sales as provinces squeeze prices http://www.fiercepharma.com/story/gsk-pfizer-among-big-pharmas-bailing-chinese-sales-provinces-squeeze-prices/2015-05-26?utm_medium=rss&utm_source=rss&utm_campaign=rss <p>When China said it would lift price caps on drugs, the move was heralded as welcome relief for drugmakers. But as <em>Bloomberg</em> reports, the optimism may have been premature. Yes, the price caps won&#39;t affect most drugs beginning June 1. But foreign drugmakers are facing pressure to cut their prices voluntarily--more than ever.</p> Asia China GlaxoSmithKline Pfizer Roche Tue, 26 May 2015 14:37:49 +0000 Tracy Staton 303931 at http://www.fiercepharma.com Investors: GSK chief Witty is safe for now, but one more strike and he's out http://www.fiercepharma.com/story/investors-gsk-chief-witty-safe-now-one-more-strike-and-hes-out/2015-05-26?utm_medium=rss&utm_source=rss&utm_campaign=rss <p>As GlaxoSmithKline charts a new course to return to growth, investors are willing to give CEO Andrew Witty some time to see it through.</p> Andrew Witty GlaxoSmithKline Tue, 26 May 2015 14:29:17 +0000 Carly Helfand 303926 at http://www.fiercepharma.com Study: Gilead's Harvoni could save U.S. and Europe billions in worker productivity http://www.fiercepharma.com/story/study-gileads-harvoni-could-save-us-and-europe-billions-worker-productivity/2015-05-26?utm_medium=rss&utm_source=rss&utm_campaign=rss <p>Gilead Sciences has a new swath of research showing that investing in new hep C therapies could potentially save the U.S. and Europe billions of dollars in lost productivity.</p> Gilead Sciences Harvoni Hepatitis C R&D Tue, 26 May 2015 13:46:54 +0000 Emily Wasserman 303921 at http://www.fiercepharma.com California's pharma-friendly copay caps could spread to other states http://www.fiercepharma.com/story/californias-pharma-friendly-copay-caps-could-spread-other-states/2015-05-26?utm_medium=rss&utm_source=rss&utm_campaign=rss <p>It&#39;s official: California&#39;s state insurance exchange has capped drug copays. After weighing the new policy for months, Covered California slapped a $250 monthly copay cap on specialty meds, with specific limits on some drugs in some plans ranging from $150 to $500.</p> copay Tue, 26 May 2015 13:41:19 +0000 Tracy Staton 303916 at http://www.fiercepharma.com The legal death of Actavis' Namenda strategy spells doom for the 'hard switch' http://www.fiercepharma.com/story/legal-death-actavis-namenda-strategy-spells-doom-hard-switch/2015-05-26?utm_medium=rss&utm_source=rss&utm_campaign=rss <p>A U.S. appeals court has officially spoiled Actavis&#39; plot to force patients over to a new, patent-protected version of Namenda to preserve the med&#39;s revenues when generics hit. So if other drugmakers are considering the tactic, they&#39;d better think twice.</p> Actavis Generics Namenda Tue, 26 May 2015 13:01:02 +0000 Carly Helfand 303911 at http://www.fiercepharma.com Pfizer could buy GSK, but would Shire or Perrigo offer better targets? http://www.fiercepharma.com/story/pfizer-could-buy-gsk-would-shire-or-perrigo-offer-better-targets/2015-05-22?utm_medium=rss&utm_source=rss&utm_campaign=rss <p>The speculation is building this week that Pfizer will either attempt another megadeal with GlaxoSmithKline or another run on AstraZeneca. Either would cut Pfizer&#39;s tax rate and give it some products to salve its various ills, lackluster stock price and poor performing portfolio. But the new thinking, like in the last 24 hours, is that smaller deals, perhaps a buyout of Shire or even Perrigo, or both, are better bets.</p> GlaxoSmithKline Perrigo Pfizer Shire Fri, 22 May 2015 15:55:11 +0000 Eric Palmer 303651 at http://www.fiercepharma.com Valeant chief Pearson won't be scared off by M&A 'bubble' http://www.fiercepharma.com/story/valeant-chief-pearson-wont-be-scared-ma-bubble/2015-05-22?utm_medium=rss&utm_source=rss&utm_campaign=rss <p>Valeant CEO J. Michael Pearson is plenty familiar with the pharma M&amp;A space; after all, he&#39;s made scores of deals since taking up the post in 2008. And the way he sees it, with pickups happening left and right in the sector, some of pharma&#39;s recent acquisitions &quot;are not going to work.&quot;</p> J. Michael Pearson M&A Valeant Fri, 22 May 2015 15:30:42 +0000 Carly Helfand 303646 at http://www.fiercepharma.com Merck's Keytruda, BMS' Opdivo score European nods to keep immuno-oncology race blazing http://www.fiercepharma.com/story/mercks-keytruda-bms-opdivo-score-european-nods-keep-immuno-oncology-race-bl/2015-05-22?utm_medium=rss&utm_source=rss&utm_campaign=rss <p>Merck&#39;s Keytruda gained some regulatory ground in Europe on Friday, nabbing a melanoma recommendation that Opdivo snagged last month. But Opdivo continued to charge ahead, too, winning a nod in lung cancer to help preserve its lead.</p> Bristol-Myers Squibb Keytruda Merck Opdivo Regulatory Fri, 22 May 2015 14:59:02 +0000 Carly Helfand 303641 at http://www.fiercepharma.com Celgene's next-gen psoriasis drug dissed by German cost watchdog http://www.fiercepharma.com/story/celgenes-next-gen-psoriasis-drug-dissed-german-cost-watchdog/2015-05-22?utm_medium=rss&utm_source=rss&utm_campaign=rss <p>Celgene&#39;s Otezla has hit a snag with the notoriously difficult German cost watchdog IQWiG, which said it just doesn&#39;t see the added benefit over treatments already on the market.</p> Celgene Otezla Fri, 22 May 2015 13:52:33 +0000 Eric Palmer 303626 at http://www.fiercepharma.com England's Cancer Drugs Fund keeps Bayer's Stivarga, axes Eisai and Lilly meds http://www.fiercepharma.com/story/englands-cancer-drugs-fund-keeps-bayers-stivarga-axes-eisai-and-lilly-meds/2015-05-22?utm_medium=rss&utm_source=rss&utm_campaign=rss <p>England&#39;s Cancer Drugs Fund has drawn a hard line when it comes to its list of covered meds, axing cancer treatments despite pushback from drugmakers. But Bayer scored a victory for its cancer med Stivarga, getting the fund to reverse its decision and keep the drug on its list even as rival companies lose similar battles.</p> Bayer Cancer Drugs Fund Regulatory Fri, 22 May 2015 13:48:36 +0000 Emily Wasserman 303621 at http://www.fiercepharma.com Want the U.K.'s NHS to quickly adopt new products, drugmakers? There's an office for that http://www.fiercepharma.com/story/want-uks-nhs-quickly-adopt-new-products-drugmakers-theres-office/2015-05-22?utm_medium=rss&utm_source=rss&utm_campaign=rss <p>Drugmakers want market access and reimbursement for their new products as fast as possible, and now, the U.K.&#39;s National Institute for Health and Care Excellence is setting up an office with the same goal.</p> NHS NICE Regulatory Fri, 22 May 2015 13:30:45 +0000 Carly Helfand 303616 at http://www.fiercepharma.com Endo sews up $9.2B financing for Par Pharma buyout http://www.fiercepharma.com/story/endo-sews-92b-financing-par-pharma-buyout/2015-05-21?utm_medium=rss&utm_source=rss&utm_campaign=rss <p>Earlier this week, Endo inked a pact to nab Par Pharmaceutical for $8 billion. But to do that, it&#39;ll need a loan, and it&#39;s agreed to a $9.275 billion loan package to back the acquisition.</p> Endo M&A Par Pharmaceutical Thu, 21 May 2015 15:33:40 +0000 Carly Helfand 303241 at http://www.fiercepharma.com CVS Health gets more drug pricing clout with $12B deal for Omnicare http://www.fiercepharma.com/story/cvs-health-gets-more-drug-pricing-clout-12b-deal-omnicare/2015-05-21?utm_medium=rss&utm_source=rss&utm_campaign=rss <p>Get ready for more of a squeeze on drugs used by seniors. CVS Health agreed to pay $12.7 billion for the pharmacy services company Omnicare, which specializes in assisted living and long-term care facilities.</p> CVS M&A Omnicare Thu, 21 May 2015 15:27:35 +0000 Tracy Staton 303236 at http://www.fiercepharma.com Report: Cadila next in line for injectables bulk-up as it nears deal for Claris http://www.fiercepharma.com/story/report-cadila-next-line-injectables-bulk-it-nears-deal-claris/2015-05-21?utm_medium=rss&utm_source=rss&utm_campaign=rss <p>India&#39;s Cadila Healthcare has emerged as the leading horse in a race to acquire the generic sterile injectables business of Claris Lifescience, and it&#39;s reportedly putting the finishing touches on a deal.</p> Cadila M&A Thu, 21 May 2015 15:21:50 +0000 Carly Helfand 303231 at http://www.fiercepharma.com Aspen unloads $301M worth of meds to fuel expansion abroad http://www.fiercepharma.com/story/aspen-unloads-301m-worth-meds-fuel-expansion-abroad/2015-05-21?utm_medium=rss&utm_source=rss&utm_campaign=rss <p>South Africa-based Aspen Pharmacare is looking to expand its global footprint, and the company is selling off two of its pharma portfolios to India&#39;s Strides Arcolab for a combined $301 million to lighten its load and put extra cash in the pot as it gears up for international growth.</p> Aspen M&A Strides Arcolab Thu, 21 May 2015 13:59:30 +0000 Emily Wasserman 303226 at http://www.fiercepharma.com Novo, Baxter spar over hemophilia patent amid ITC probe http://www.fiercepharma.com/story/novo-baxter-spar-over-hemophilia-patent-amid-itc-probe/2015-05-21?utm_medium=rss&utm_source=rss&utm_campaign=rss <p>Baxter said back in March that Novo Nordisk&#39;s recently launched hemophilia med infringed some of its patents, spurring an investigation from the U.S. International Trade Commission. But the Danish drugmaker doesn&#39;t see what all the fuss is about.</p> Baxter hemophilia Novo Nordisk Regulatory Thu, 21 May 2015 13:55:26 +0000 Carly Helfand 303221 at http://www.fiercepharma.com German cost watchdogs look askance at uniQure's $1.4M gene therapy http://www.fiercepharma.com/story/german-cost-watchdogs-look-askance-uniqures-14m-gene-therapy/2015-05-21?utm_medium=rss&utm_source=rss&utm_campaign=rss <p>German cost-effectiveness watchdogs aren&#39;t among pharma&#39;s favorite people. Since lawmakers instituted a tough price-setting process, state officials have questioned the benefits of one new drug after another--to the point where some drugmakers decided not to launch there at all.</p> Europe Germany Glybera Sales and Marketing uniQure Thu, 21 May 2015 13:54:51 +0000 Tracy Staton 303216 at http://www.fiercepharma.com ProPublica: Safety questions over GSK's Advair linger after years on the asthma throne http://www.fiercepharma.com/story/propublica-safety-questions-over-gsks-advair-linger-after-years-asthma-thro/2015-05-20?utm_medium=rss&utm_source=rss&utm_campaign=rss <p>U.S. regulators gave GlaxoSmithKline&#39;s Advair the green light a decade and a half ago, paving the way for a long reign that saw the med grow to more than $8 billion in annual sales. But even after all these years, whether Advair poses a higher risk of asthma-related death remains unclear, <em>ProPublica</em> says.</p> Advair Drug Safety GlaxoSmithKline Wed, 20 May 2015 15:41:00 +0000 Carly Helfand 302766 at http://www.fiercepharma.com Hep C landscape shifts again as BMS combo nabs breakthrough tag http://www.fiercepharma.com/story/hep-c-landscape-shifts-again-bms-combo-nabs-breakthrough-tag/2015-05-20?utm_medium=rss&utm_source=rss&utm_campaign=rss <p>Gilead Sciences and AbbVie caught a break for their hepatitis C treatments when the FDA rescinded breakthrough designations earlier this year for potential competitors being developed by Merck and Bristol-Myers Squibb.</p> Bristol-Myers Squibb Regulatory Wed, 20 May 2015 15:38:40 +0000 Eric Palmer 302761 at http://www.fiercepharma.com